

## **Don McCaffrey** **President and Chief Executive Officer**

Mr. McCaffrey is President and Chief Executive Officer of Resverlogix Corp. He has over 38 years of corporate management experience including over 18 years in drug discovery & development. Don co-founded Resverlogix in 2001 with Dr. Norman Wong. Don's expertise in corporate operations has attracted an international team of experts to the



company, including world renowned Key Opinion Leaders in the fields of cardiology, endocrinology and nephrology. The company's lead drug – apabetalone (RVX-208) – is currently in a fully-enrolled, Phase 3 clinical trial – BETonMACE. Due to Don's efforts, apabetalone has an 8-year lead on the market as the first epigenetic drug for the reduction of Major Adverse Cardiac Events. Don has strategically directed the company in its continued partnering discussions with global pharmaceutical companies, establishing one of the largest China biotech partnerships to date with Shenzhen Hepalink Pharmaceuticals. Don is also the co-founder, President and CEO of Zenith Epigenetics, a private, clinical stage biotechnology company focused on the discovery and development of novel therapeutics for the treatment of cancer and other disorders with significant unmet medical need.

Don's passion lies in supporting non-profit organizations, especially those that support education and the development of future generations of young scientists. Don's personal donation to the Mount Royal University contributed to the Roderick Mah Centre for Continuous Learning, which supports student facilities within the health and sciences programs. The building is one of North America's most environmentally sustainable, technologically advanced and designed for learning.